ONO-2370 a Phase 2 Double-Blind, Randomised, Placebo-Controlled, Parallel-Group study, and an Open-Label, Uncontrolled, Multicenter, Long-term, Extension study
Latest Information Update: 18 Jul 2022
At a glance
- Drugs Opicapone (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Acronyms Comfort-PD
- Sponsors Ono Pharmaceutical
- 19 Oct 2020 Results of double-blind part of comfort PD study published in the Movement Disorders
- 22 May 2017 Status changed from recruiting to active, no longer recruiting.
- 09 Jun 2016 New trial record